Ideaya Biosciences Inc (IDYA) Implied Volatility Current

Tracking IDYA implied volatility helps you identify when options premiums on Ideaya Biosciences Inc are historically cheap or expensive, and where the best trades are hiding. Ideaya Biosciences Inc implied volatility reflects the market's expectation of future price movement: when IDYA IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Ideaya Biosciences Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For IDYA, tracking metrics like IDYA IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on IDYA signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability.

The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where IDYA implied volatility sits today versus where it has been. Our scanner ranks Ideaya Biosciences Inc implied volatility against its historical range, surfaces extremes in IDYA IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Ideaya Biosciences Inc IV is rich or cheap — measure it, then act on it.